Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

Nanchahal, J., Ball, C., Rombach, I. orcid.org/0000-0003-3464-3867 et al. (9 more authors) (2022) Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial. The Lancet Rheumatology, 4 (6). E407-E416. ISSN 2665-9913

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. (https://creativecommons.org/licenses/by/4.0/)

Dates:
  • Published: 1 June 2022
  • Published (online): 29 April 2022
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > ScHARR - Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 20 May 2022 17:32
Last Modified: 04 Nov 2022 16:05
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: 10.1016/s2665-9913(22)00093-5
Open Archives Initiative ID (OAI ID):

Export

Statistics